{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:41Z","timestamp":1792831061456,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02376-0","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:53:31Z","timestamp":1790128411000},"page":"1795-1812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Progress and Successes"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-4362","authenticated-orcid":false,"given":"Maria Giovanna","family":"Puoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-9493","authenticated-orcid":false,"given":"Anna O. J.","family":"Oorthuys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8085-3465","authenticated-orcid":false,"given":"Nicolaas Koen","family":"Vermeijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-9188","authenticated-orcid":false,"given":"Marc A.","family":"Benninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-0508","authenticated-orcid":false,"given":"Osvaldo","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"6","key":"2376_CR1","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2016.02.015","volume":"150","author":"JS Hyams","year":"2016","unstructured":"Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology. 2016;150(6):1456\u201368. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.015.","journal-title":"Gastroenterology"},{"issue":"6","key":"2376_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","volume":"150","author":"BE Lacy","year":"2016","unstructured":"Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393\u2013407. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.031.","journal-title":"Gastroenterology"},{"issue":"6","key":"2376_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262\u201379. https:\/\/doi.org\/10.1053\/j.gastro.2016.02.032.","journal-title":"Gastroenterology"},{"issue":"11","key":"2376_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.dld.2009.07.006","volume":"41","author":"J Gunnarsson","year":"2009","unstructured":"Gunnarsson J, Simren M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis. 2009;41(11):788\u201393. https:\/\/doi.org\/10.1016\/j.dld.2009.07.006.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"2376_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrgastro.2010.4","volume":"7","author":"L Ohman","year":"2010","unstructured":"Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163\u201373. https:\/\/doi.org\/10.1038\/nrgastro.2010.4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"25","key":"2376_CR6","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.3748\/wjg.v21.i25.7621","volume":"21","author":"M El-Salhy","year":"2015","unstructured":"El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2015;21(25):7621\u201336. https:\/\/doi.org\/10.3748\/wjg.v21.i25.7621.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2376_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/gutjnl-2015-311240","volume":"66","author":"AD Sperber","year":"2017","unstructured":"Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome foundation working team literature review. Gut. 2017;66(6):1075\u201382. https:\/\/doi.org\/10.1136\/gutjnl-2015-311240.","journal-title":"Gut"},{"issue":"5","key":"2376_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126982","volume":"10","author":"JJ Korterink","year":"2015","unstructured":"Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta- analysis. PLoS ONE. 2015;10(5):e0126982. https:\/\/doi.org\/10.1371\/journal.pone.0126982.","journal-title":"PLoS ONE"},{"issue":"1","key":"2376_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpeds.2014.08.022","volume":"166","author":"JW Varni","year":"2015","unstructured":"Varni JW, Bendo CB, Nurko S, Shulman RJ, Self MM, Franciosi JP, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85\u201390. https:\/\/doi.org\/10.1016\/j.jpeds.2014.08.022.","journal-title":"J Pediatr"},{"issue":"5","key":"2376_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/MPG.0000000000000850","volume":"61","author":"A Assa","year":"2015","unstructured":"Assa A, Ish-Tov A, Rinawi F, Shamir R. School attendance in children with functional abdominal pain and inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2015;61(5):553\u20137. https:\/\/doi.org\/10.1097\/MPG.0000000000000850.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2376_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/apt.15325","volume":"50","author":"M Zamani","year":"2019","unstructured":"Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132\u201343. https:\/\/doi.org\/10.1111\/apt.15325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2376_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jpeds.2015.07.058","volume":"167","author":"DR Hoekman","year":"2015","unstructured":"Hoekman DR, Rutten J, Vlieger AM, Benninga MA, Dijkgraaf MGW. Annual costs of care for pediatric irritable bowel syndrome, functional abdominal pain, and functional abdominal pain syndrome. J Pediatr. 2015;167(5):1103-8.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2015.07.058.","journal-title":"J Pediatr"},{"issue":"1","key":"2376_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MPG.0b013e3181e67058","volume":"52","author":"RS Choung","year":"2011","unstructured":"Choung RS, Shah ND, Chitkara D, Branda ME, Van Tilburg MA, Whitehead WE, et al. Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. J Pediatr Gastroenterol Nutr. 2011;52(1):47\u201354. https:\/\/doi.org\/10.1097\/MPG.0b013e3181e67058.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2376_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1053\/j.gastro.2006.03.008","volume":"130","author":"DA Drossman","year":"2006","unstructured":"Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377\u201390. https:\/\/doi.org\/10.1053\/j.gastro.2006.03.008.","journal-title":"Gastroenterology"},{"issue":"3","key":"2376_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/MPG.0b013e31815bc1c1","volume":"47","author":"MJ Gieteling","year":"2008","unstructured":"Gieteling MJ, Bierma-Zeinstra SMA, Passchier J, Berger MY. Prognosis of chronic or recurrent abdominal pain in children. J Pediatr Gastroenterol Nutr. 2008;47(3):316\u201326. https:\/\/doi.org\/10.1097\/MPG.0b013e31815bc1c1.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"2376_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/ajg.2011.487","volume":"107","author":"AM Vlieger","year":"2012","unstructured":"Vlieger AM, Rutten J, Govers A, Frankenhuis C, Benninga MA. Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol. 2012;107(4):627\u201331. https:\/\/doi.org\/10.1038\/ajg.2011.487.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2376_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S2352-4642(25)00058-6","volume":"9","author":"V Sinopoulou","year":"2025","unstructured":"Sinopoulou V, Groen J, Gordon M, Mougey E, Franciosi JP, de Meij TGJ, et al. Efficacy of interventions for the treatment of irritable bowel syndrome, functional abdominal pain\u2014not otherwise specified, and abdominal migraine in children: a systematic review and network meta-analysis. Lancet Child Adolesc Health. 2025;9(5):315\u201324. https:\/\/doi.org\/10.1016\/S2352-4642(25)00058-6.","journal-title":"Lancet Child Adolesc Health."},{"issue":"2","key":"2376_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jpeds.2014.09.067","volume":"166","author":"JJ Korterink","year":"2015","unstructured":"Korterink JJ, Rutten J, Venmans L, Benninga MA, Tabbers MM. Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review. J Pediatr. 2015;166(2):424-31.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2014.09.067.","journal-title":"J Pediatr"},{"issue":"10","key":"2376_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/ajg.2014.202","volume":"109","author":"AC Ford","year":"2014","unstructured":"Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito JA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547\u201361. https:\/\/doi.org\/10.1038\/ajg.2014.202.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2376_CR20","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/ajg.2014.148","volume":"109","author":"AC Ford","year":"2014","unstructured":"Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1350\u201365. https:\/\/doi.org\/10.1038\/ajg.2014.148.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2376_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/ajg.2014.195","volume":"109","author":"P Moayyedi","year":"2014","unstructured":"Moayyedi P, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367\u201374. https:\/\/doi.org\/10.1038\/ajg.2014.195.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2376_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","volume":"146","author":"EP Halmos","year":"2014","unstructured":"Halmos EP, Power VA, Shepherd SJ, Gibson PR, Miur JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. https:\/\/doi.org\/10.1053\/j.gastro.2013.09.046.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"2376_CR23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/ajg.2014.187","volume":"109","author":"AC Ford","year":"2014","unstructured":"Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2-26. https:\/\/doi.org\/10.1038\/ajg.2014.187.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2376_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/jpn3.70070","volume":"81","author":"J Groen","year":"2025","unstructured":"Groen J, Gordon M, Chogle A, Benninga M, Borlack R, Borrelli O, et al. ESPGHAN\/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4\u201318 years. J Pediatr Gastroenterol Nutr. 2025;81(2):442\u201371. https:\/\/doi.org\/10.1002\/jpn3.70070.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2376_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/pch\/pxy121","volume":"24","author":"M Eltorki","year":"2019","unstructured":"Eltorki M, Bhattacharjee A, Khan M, Martin E, Shyleyko R, Freedman SB. Treatment failure in children diagnosed with constipation in a paediatric emergency department in relation to Rome III criteria. Paediatr Child Health. 2019;24(3):185\u201392. https:\/\/doi.org\/10.1093\/pch\/pxy121.","journal-title":"Paediatr Child Health"},{"issue":"18","key":"2376_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/nu15184070","volume":"15","author":"G Chiarioni","year":"2023","unstructured":"Chiarioni G, Popa SL, Ismaiel A, Pop C, Dumitrascu DI, Brata VD, et al. The effect of polyphenols, minerals, fibers, and fruits on irritable bowel syndrome: a systematic review. Nutrients. 2023;15(18):4070. https:\/\/doi.org\/10.3390\/nu15184070.","journal-title":"Nutrients"},{"issue":"2","key":"2376_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.25122\/jml-2022-0028","volume":"15","author":"AN Galica","year":"2022","unstructured":"Galica AN, Galica R, Dumitrascu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life. 2022;15(2):174\u20139. https:\/\/doi.org\/10.25122\/jml-2022-0028.","journal-title":"J Med Life"},{"issue":"20","key":"2376_CR28","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3748\/wjg.v19.i20.3062","volume":"19","author":"A Horvath","year":"2013","unstructured":"Horvath A, Dziechciarz P, Szajewska H. Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: a randomized trial. World J Gastroenterol. 2013;19(20):3062\u20138. https:\/\/doi.org\/10.3748\/wjg.v19.i20.3062.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2376_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3748\/wjg.v19.i2.235","volume":"19","author":"C Romano","year":"2013","unstructured":"Romano C, Comito D, Famiani A, Calamar\u00e0 S, Loddo I. Partially hydrolyzed guar gum in pediatric functional abdominal pain. World J Gastroenterol. 2013;19(2):235\u201340. https:\/\/doi.org\/10.3748\/wjg.v19.i2.235.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2376_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/MPG.0000000000003622","volume":"76","author":"J Menon","year":"2023","unstructured":"Menon J, Thapa BR, Kumari R, Kadyada SP, Rana S, Lal SB. Efficacy of oral psyllium in pediatric irritable bowel syndrome: a double-blind randomized control trial. J Pediatr Gastroenterol Nutr. 2023;76(1):14\u20139. https:\/\/doi.org\/10.1097\/MPG.0000000000003622.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2376_CR31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2016.03.045","volume":"15","author":"RJ Shulman","year":"2017","unstructured":"Shulman RJ, Hollister EB, Cain K, Czyzewski DI, Self MM, Weidler EM, et al. Psyllium fiber reduces abdominal pain in children with irritable bowel syndrome in a randomized, double-blind trial. Clin Gastroenterol Hepatol. 2017;15(5):712-9.e4. https:\/\/doi.org\/10.1016\/j.cgh.2016.03.045.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2376_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17474124.2022.2055547","volume":"16","author":"CM de Bruijn","year":"2022","unstructured":"de Bruijn CM, Rexwinkel R, Gordon M, Sinopoulou V, Benninga MA, Tabbers MM. Dietary interventions for functional abdominal pain disorders in children: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(4):359\u201371. https:\/\/doi.org\/10.1080\/17474124.2022.2055547.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9","key":"2376_CR33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3109\/00365521.2011.584895","volume":"46","author":"PA Waller","year":"2011","unstructured":"Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057\u201364. https:\/\/doi.org\/10.3109\/00365521.2011.584895.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"2376_CR34","doi-asserted-by":"publisher","first-page":"Cd012849","DOI":"10.1002\/14651858.CD012849.pub2","volume":"2","author":"C Wallace","year":"2023","unstructured":"Wallace C, Gordon M, Sinopoulou V, Akobeng AK. Probiotics for management of functional abdominal pain disorders in children. Cochrane Database Syst Rev. 2023;2(2):Cd012849. https:\/\/doi.org\/10.1002\/14651858.CD012849.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2376_CR35","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1111\/j.1440-1754.2010.01797.x","volume":"50","author":"C Romano","year":"2014","unstructured":"Romano C, Ferrau V, Cavataio F, Iacono G, Spina M, Lionetti E, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50(10):E68-71. https:\/\/doi.org\/10.1111\/j.1440-1754.2010.01797.x.","journal-title":"J Paediatr Child Health"},{"key":"2376_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jpeds.2016.04.003","volume":"174","author":"Z Weizman","year":"2016","unstructured":"Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2016.04.003.","journal-title":"J Pediatr"},{"issue":"12","key":"2376_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3345\/cep.2019.01613","volume":"63","author":"P Rahmani","year":"2020","unstructured":"Rahmani P, Orimi AG, Motamed F, Moradzadeh A. Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain. Clin Exp Pediatr. 2020;63(12):485\u201390. https:\/\/doi.org\/10.3345\/cep.2019.01613.","journal-title":"Clin Exp Pediatr."},{"issue":"6","key":"2376_CR38","doi-asserted-by":"publisher","DOI":"10.5812\/ijp.2616","volume":"25","author":"K Eftekhari","year":"2015","unstructured":"Eftekhari K, Vahedi Z, Aghdam MK, Diaz DN. A randomized double-blind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr. 2015;25(6):e2616. https:\/\/doi.org\/10.5812\/ijp.2616.","journal-title":"Iran J Pediatr"},{"issue":"11","key":"2376_CR39","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/apa.13992","volume":"106","author":"M Maragkoudaki","year":"2017","unstructured":"Maragkoudaki M, Chouliaras G, Orel R, Horvath A, Szajewska H, Papadopoulou A. Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr. 2017;106(11):1857\u201362. https:\/\/doi.org\/10.1111\/apa.13992.","journal-title":"Acta Paediatr"},{"issue":"6","key":"2376_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/MPG.0000000000001478","volume":"64","author":"O Jadresin","year":"2017","unstructured":"Jadresin O, Hojsak I, Misak Z, Kekez AJ, Trbojevi\u0107 T, Ivkovi\u0107 L, et al. Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children: RCT study. J Pediatr Gastroenterol Nutr. 2017;64(6):925\u20139. https:\/\/doi.org\/10.1097\/MPG.0000000000001478.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"2376_CR41","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1016\/j.clnu.2020.04.019","volume":"39","author":"O Jadresin","year":"2020","unstructured":"Jadresin O, Sila S, Trivic I, Mi\u0161ak Z, Kola\u010dek S, Hojsak I. Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: results of the double-blind randomized study. Clin Nutr. 2020;39(12):3645\u201351. https:\/\/doi.org\/10.1016\/j.clnu.2020.04.019.","journal-title":"Clin Nutr"},{"issue":"6","key":"2376_CR42","doi-asserted-by":"publisher","first-page":"e1445","DOI":"10.1542\/peds.2010-0467","volume":"126","author":"R Francavilla","year":"2010","unstructured":"Francavilla R, Miniello V, Magist\u00e0 AM, De Canio A, Bucci N, Gagliardi F, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126(6):e1445\u201352. https:\/\/doi.org\/10.1542\/peds.2010-0467.","journal-title":"Pediatrics"},{"issue":"5","key":"2376_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.14661\/1255","volume":"7","author":"H Kianifar","year":"2015","unstructured":"Kianifar H, Jafari SA, Kiani M, Ahanchian H, Ghasemi SV, Grover Z, et al. Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Electron Physician. 2015;7(5):1255\u201360. https:\/\/doi.org\/10.14661\/1255.","journal-title":"Electron Physician"},{"issue":"2","key":"2376_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2036.2006.03175.x","volume":"25","author":"A Gawronska","year":"2007","unstructured":"Gawronska A, Dziechciarz P, Horvath A, Szajewska H, et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177\u201384. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03175.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2376_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpeds.2005.05.015","volume":"147","author":"M Bauserman","year":"2005","unstructured":"Bauserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147(2):197\u2013201. https:\/\/doi.org\/10.1016\/j.jpeds.2005.05.015.","journal-title":"J Pediatr"},{"issue":"2","key":"2376_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2036.1988.tb00677.x","volume":"2","author":"M Hawthorn","year":"1988","unstructured":"Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2(2):101\u201318. https:\/\/doi.org\/10.1111\/j.1365-2036.1988.tb00677.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2376_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041044","volume":"11","author":"J Daniluk","year":"2022","unstructured":"Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The efficacy of mebeverine in the treatment of irritable bowel syndrome\u2014a systematic review. J Clin Med. 2022;11(4):1044. https:\/\/doi.org\/10.3390\/jcm11041044.","journal-title":"J Clin Med"},{"issue":"6","key":"2376_CR48","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-042101","volume":"147","author":"R Rexwinkel","year":"2021","unstructured":"Rexwinkel R, de Bruijn CMA, Gordon M, Benninga MA, Tabbers MM. Pharmacologic treatment in functional abdominal pain disorders in children: a systematic review. Pediatrics. 2021;147(6):e2020042101. https:\/\/doi.org\/10.1542\/peds.2020-042101.","journal-title":"Pediatrics"},{"issue":"1","key":"2376_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.gastro.2025.02.030","volume":"169","author":"R Rexwinkel","year":"2025","unstructured":"Rexwinkel R, Verdeijden NK, Zeevenhooven J, Kelder J, Groeneweg M, Hummel T, et al. Mebeverine and the influence of labeling in adolescents with irritable bowel syndrome or functional abdominal pain not otherwise specified: a 2 \u00d7 2 randomized, placebo-controlled trial. Gastroenterology. 2025;169(1):94\u2013103. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.030.","journal-title":"Gastroenterology"},{"issue":"6","key":"2376_CR50","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/apt.14519","volume":"47","author":"BP Chumpitazi","year":"2018","unstructured":"Chumpitazi BP, Kearns GL, Shulman RJ. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther. 2018;47(6):738\u201352. https:\/\/doi.org\/10.1111\/apt.14519.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2376_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1067\/mpd.2001.109606","volume":"138","author":"RM Kline","year":"2001","unstructured":"Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125\u20138. https:\/\/doi.org\/10.1067\/mpd.2001.109606.","journal-title":"J Pediatr"},{"issue":"4","key":"2376_CR52","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.17(4)2015.23844","volume":"17","author":"M Asgarshirazi","year":"2015","unstructured":"Asgarshirazi M, Shariat M, Dalili H. Comparison of the effects of pH-dependent peppermint oil and synbiotic lactol (bacillus coagulans + fructooligosaccharides) on childhood functional abdominal pain: a randomized placebo-controlled study. Iran Red Crescent Med J. 2015;17(4):e23844. https:\/\/doi.org\/10.5812\/ircmj.17(4)2015.23844.","journal-title":"Iran Red Crescent Med J"},{"issue":"2014","key":"2376_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/191026","volume":"2014","author":"Z Pourmoghaddas","year":"2014","unstructured":"Pourmoghaddas Z, Saneian H, Roohafza H, Gholamrezaei A. Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Biomed Res Int. 2014;2014(2014):191026. https:\/\/doi.org\/10.1155\/2014\/191026.","journal-title":"Biomed Res Int"},{"issue":"10","key":"2376_CR54","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13312-015-0730-y","volume":"52","author":"M Narang","year":"2015","unstructured":"Narang M, Shah D, Akhtar H. Efficacy and safety of drotaverine hydrochloride in children with recurrent abdominal pain: a randomized placebo controlled trial. Indian Pediatr. 2015;52(10):847\u201351. https:\/\/doi.org\/10.1007\/s13312-015-0730-y.","journal-title":"Indian Pediatr"},{"issue":"5","key":"2376_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/030006059702500501","volume":"25","author":"M Delvaux","year":"1997","unstructured":"Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225\u201346. https:\/\/doi.org\/10.1177\/030006059702500501.","journal-title":"J Int Med Res"},{"issue":"1","key":"2376_CR56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5056\/jnm.2013.19.1.90","volume":"19","author":"GS Karabulut","year":"2013","unstructured":"Karabulut GS, Beser OF, Erginoz E, Kutlu T, Coku\u011fra\u015f F\u00c7, Erkan T. The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment. J Neurogastroenterol Motil. 2013;19(1):90\u20133. https:\/\/doi.org\/10.5056\/jnm.2013.19.1.90.","journal-title":"J Neurogastroenterol Motil."},{"issue":"9","key":"2376_CR57","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2165\/00003495-200767090-00007","volume":"67","author":"GN Tytgat","year":"2007","unstructured":"Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343\u201357. https:\/\/doi.org\/10.2165\/00003495-200767090-00007.","journal-title":"Drugs"},{"issue":"48","key":"2376_CR58","doi-asserted-by":"publisher","first-page":"E1612","DOI":"10.1503\/cmaj.201055","volume":"192","author":"N Poonai","year":"2020","unstructured":"Poonai N, Kumar K, Coriolano K, Thompson G, Brahmbhatt S, Dzongowski E, et al. Hyoscine butylbromide versus acetaminophen for nonspecific colicky abdominal pain in children: a randomized controlled trial. CMAJ. 2020;192(48):E1612\u20139. https:\/\/doi.org\/10.1503\/cmaj.201055.","journal-title":"CMAJ"},{"key":"2376_CR59","unstructured":"FDA Briefing Document. Joint meeting of the gastrointestinal drugs advisory committee and drug safety and risk management advisory committees. https:\/\/www.fda.gov\/media\/119011\/download. Accessed 4 July 2026."},{"issue":"1","key":"2376_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2036.2006.02705.x","volume":"23","author":"V Khoshoo","year":"2006","unstructured":"Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(1):191\u20136. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02705.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2376_CR61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MPG.0000000000002192","volume":"68","author":"D Jarzebicka","year":"2019","unstructured":"Jarzebicka D, Sieczkowska\u2010Golub J, Kierkus J, Czubkowski P, Kowalczuk-Kryston M, Pelc M, et al. PEG 3350 versuslactulose for treatment offunctional constipation in children: randomized study. J Pediatr Gastroenterol Nutr. 2019;68(3):318\u201324. https:\/\/doi.org\/10.1097\/MPG.0000000000002192.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2376_CR62","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1542\/peds.2006-0220","volume":"118","author":"V Loening\u2010Baucke","year":"2006","unstructured":"Loening\u2010Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics. 2006;118(2):528\u201335. https:\/\/doi.org\/10.1542\/peds.2006-0220.","journal-title":"Pediatrics"},{"issue":"3","key":"2376_CR63","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MPG.0000000000002795","volume":"71","author":"S Bonilla","year":"2020","unstructured":"Bonilla S, Nurko S, Rodriguez L. Long\u2010term use of bisacodyl in pediatric functional constipation refractory to conventional therapy. J Pediatr Gastroenterol Nutr. 2020;71(3):288\u201391. https:\/\/doi.org\/10.1097\/MPG.0000000000002795.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"2376_CR64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jpedsurg.2018.01.002","volume":"53","author":"A Vilanova\u2010Sanchez","year":"2018","unstructured":"Vilanova\u2010Sanchez A, Gasior AC, Toocheck N, Weaver L, Wood RJ, Reck CA, et al. Are senna basedlaxatives safe when used as long term treatment for constipation in children. J Pediatr Surg. 2018;53(4):722\u20137. https:\/\/doi.org\/10.1016\/j.jpedsurg.2018.01.002.","journal-title":"J Pediatr Surg"},{"key":"2376_CR65","doi-asserted-by":"publisher","unstructured":"Gordon M, de Geus A, Boruta M, Banasiuk M, Benninga M, Borrelli O, et al. European Society for Paediatric Gastroenterology, Hepatology and Nutrition\/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0\u201318 years. J Pediatr Gastroenterol Nutr. 2026. https:\/\/doi.org\/10.1002\/jpn3.70447. (Online ahead of print).","DOI":"10.1002\/jpn3.70447"},{"issue":"5","key":"2376_CR66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/MPG.0000000000001819","volume":"66","author":"A Karunanayake","year":"2018","unstructured":"Karunanayake A, Devanarayana N, de Silva A, Gunawardena S, Rajindrajith S. Randomized controlled clinical trial on value of domperidone in functional abdominal pain in children. J Pediatr Gastroenterol Nutr. 2018;66(5):725\u201331. https:\/\/doi.org\/10.1097\/MPG.0000000000001819.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2376_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/MPG.0b013e318292f9ea","volume":"57","author":"H Winter","year":"2013","unstructured":"Winter H, Di Lorenzo C, Benninga M, Gilger MA, Kearns GL, Hyman PE, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57(2):197\u2013203. https:\/\/doi.org\/10.1097\/MPG.0b013e318292f9ea.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"2376_CR68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/01.mpg.0000304454.99799.42","volume":"46","author":"O Liem","year":"2008","unstructured":"Liem O, Mousa H, Benninga M, Di Lorenzo C. Tegaserod use in children: a single-center experience. J Pediatr Gastroenterol Nutr. 2008;46(1):54\u20138. https:\/\/doi.org\/10.1097\/01.mpg.0000304454.99799.42.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"2376_CR69","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1067\/mpd.2001.118883","volume":"139","author":"C Di Lorenzo","year":"2001","unstructured":"Di Lorenzo C, Youssef NN, Sigurdsson L, Scharff L, Griffiths J, Wald A. Visceral hyperalgesia in children with functional abdominal pain. J Pediatr. 2001;139(6):838\u201343. https:\/\/doi.org\/10.1067\/mpd.2001.118883.","journal-title":"J Pediatr"},{"issue":"7","key":"2376_CR70","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1440-1746.1998.tb00723.x","volume":"13","author":"M Rajagopalan","year":"1998","unstructured":"Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13(7):738\u201341. https:\/\/doi.org\/10.1111\/j.1440-1746.1998.tb00723.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2376_CR71","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1161\/01.cir.99.7.979","volume":"99","author":"H Gutgesell","year":"1999","unstructured":"Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1999;99(7):979\u201382. https:\/\/doi.org\/10.1161\/01.cir.99.7.979.","journal-title":"Circulation"},{"issue":"5","key":"2376_CR72","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jpeds.2007.10.012","volume":"152","author":"RJ Bahar","year":"2008","unstructured":"Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr. 2008;152(5):685\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2007.10.012.","journal-title":"J Pediatr"},{"issue":"4","key":"2376_CR73","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2009.06.060","volume":"137","author":"M Saps","year":"2009","unstructured":"Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology. 2009;137(4):1261\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2009.06.060.","journal-title":"Gastroenterology"},{"issue":"4","key":"2376_CR74","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jgh.15765","volume":"37","author":"J Seetharaman","year":"2022","unstructured":"Seetharaman J, Poddar U, Yachha SK, Srivastava A, Sarma MS. Efficacy of amitriptyline in pediatric functional abdominal pain disorders: a randomized placebo-controlled trial. J Gastroenterol Hepatol. 2022;37(4):685\u201391. https:\/\/doi.org\/10.1111\/jgh.15765.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2376_CR75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00003495-200161030-00001","volume":"61","author":"F De Ponti","year":"2001","unstructured":"De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317\u201332. https:\/\/doi.org\/10.2165\/00003495-200161030-00001.","journal-title":"Drugs"},{"issue":"1","key":"2376_CR76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","volume":"132","author":"MD Gershon","year":"2007","unstructured":"Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397\u2013414. https:\/\/doi.org\/10.1053\/j.gastro.2006.11.002.","journal-title":"Gastroenterology"},{"issue":"10","key":"2376_CR77","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/01.chi.0000136563.31709.b0","volume":"43","author":"JV Campo","year":"2004","unstructured":"Campo JV, Perel J, Lucas A, Bridge J, Ehmann M, Kalas C, et al. Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1234\u201342. https:\/\/doi.org\/10.1097\/01.chi.0000136563.31709.b0.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"2376_CR78","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/nmo.12444","volume":"26","author":"H Roohafza","year":"2014","unstructured":"Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil. 2014;26(11):1642\u201350. https:\/\/doi.org\/10.1111\/nmo.12444.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"2376_CR79","doi-asserted-by":"publisher","first-page":"Cd008013","DOI":"10.1002\/14651858.CD008013.pub3","volume":"2","author":"CMA de Bruijn","year":"2021","unstructured":"de Bruijn CMA, Rexwinkel R, Gordon M, Benninga M, Tabbers MM. Antidepressants for functional abdominal pain disorders in children and adolescents. Cochrane Database Syst Rev. 2021;2(2):Cd008013. https:\/\/doi.org\/10.1002\/14651858.CD008013.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"2376_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1004409.","journal-title":"N Engl J Med"},{"issue":"2","key":"2376_CR81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5009\/gnl16126","volume":"11","author":"UC Ghoshal","year":"2017","unstructured":"Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196\u2013208. https:\/\/doi.org\/10.5009\/gnl16126.","journal-title":"Gut Liver"},{"issue":"4","key":"2376_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002534","volume":"95","author":"J Li","year":"2016","unstructured":"Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore). 2016;95(4):e2534. https:\/\/doi.org\/10.1097\/MD.0000000000002534.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2376_CR83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/MPG.0b013e3181effa3b","volume":"52","author":"BS Collins","year":"2011","unstructured":"Collins BS, Lin HC. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. J Pediatr Gastroenterol Nutr. 2011;52(4):382\u20136. https:\/\/doi.org\/10.1097\/MPG.0b013e3181effa3b.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"2376_CR84","first-page":"1314","volume":"17","author":"E Scarpellini","year":"2013","unstructured":"Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013;17(10):1314\u201320.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"2376_CR85","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/MPG.0b013e31823a29a7","volume":"54","author":"K Heyland","year":"2012","unstructured":"Heyland K, Friedt M, Buehr P, Braegger CP. No advantage for antibiotic treatment over placebo in Blastocystis hominis-positive children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr. 2012;54(5):677\u20139. https:\/\/doi.org\/10.1097\/MPG.0b013e31823a29a7.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"2376_CR86","first-page":"1367","volume":"60","author":"M Sadeghian","year":"2008","unstructured":"Sadeghian M. Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial. Minerva Pediatr. 2008;60(6):1367\u201374.","journal-title":"Minerva Pediatr"},{"issue":"12","key":"2376_CR87","first-page":"749","volume":"19","author":"DM Brenner","year":"2023","unstructured":"Brenner DM. Mechanism of action considerations in the management of IBS-C. Gastroenterol Hepatol (NY). 2023;19(12):749\u201356.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"2376_CR88","unstructured":"FDA approves 1st drug for children 7 years and older with irritable bowel syndrome with constipation. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-1st-drug-children-7-years-and-older-irritable-bowel-syndrome-constipation. Accessed 11 May 2025."},{"key":"2376_CR89","doi-asserted-by":"publisher","first-page":"F342","DOI":"10.1152\/ajprenal.1994.266.2.F342","volume":"266","author":"T Kita","year":"1994","unstructured":"Kita T, Smith CE, Fok KF, Duffin KL, Moore WM, Karabatsos PJ, et al. Characterization of human uroguanylin: a member of the guanylin peptide family. Am J Physiol. 1994;266:F342\u20138. https:\/\/doi.org\/10.1152\/ajprenal.1994.266.2.F342.","journal-title":"Am J Physiol"},{"key":"2376_CR90","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1073\/pnas.90.22.10464","volume":"90","author":"FK Hamra","year":"1993","unstructured":"Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA. 1993;90:10464\u20138. https:\/\/doi.org\/10.1073\/pnas.90.22.10464.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19\u201320","key":"2376_CR91","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","volume":"86","author":"AP Bryant","year":"2010","unstructured":"Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86(19\u201320):760\u20135. https:\/\/doi.org\/10.1016\/j.lfs.2010.03.015.","journal-title":"Life Sci"},{"key":"2376_CR92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0167-0115(99)00033-6","volume":"81","author":"LR Forte","year":"1999","unstructured":"Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept. 1999;81:25\u201339. https:\/\/doi.org\/10.1016\/s0167-0115(99)00033-6.","journal-title":"Regul Pept"},{"issue":"3","key":"2376_CR93","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","volume":"133","author":"V Andresen","year":"2007","unstructured":"Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133(3):761\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2007.06.067.","journal-title":"Gastroenterology"},{"issue":"3","key":"2376_CR94","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1365-2982.2009.01385.x","volume":"22","author":"H Eutamene","year":"2010","unstructured":"Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22(3):312-e84. https:\/\/doi.org\/10.1111\/j.1365-2982.2009.01385.x.","journal-title":"Neurogastroenterol Motil"},{"key":"2376_CR95","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.14309\/00000434-200410001-00863","volume":"99","author":"L Bueno","year":"2004","unstructured":"Bueno L, Beaufraud C, Mahajan-Miklos S, Bryant AP, Currie MG. Antinociceptive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain. Am J Gastroentrerol. 2004;99:S283. https:\/\/doi.org\/10.14309\/00000434-200410001-00863.","journal-title":"Am J Gastroentrerol."},{"issue":"1\u20133","key":"2376_CR96","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","volume":"649","author":"RW Busby","year":"2010","unstructured":"Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649(1\u20133):328\u201335. https:\/\/doi.org\/10.1016\/j.ejphar.2010.09.019.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2376_CR97","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1124\/jpet.112.199430","volume":"344","author":"RW Busby","year":"2013","unstructured":"Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013;344(1):196\u2013206. https:\/\/doi.org\/10.1124\/jpet.112.199430.","journal-title":"J Pharmacol Exp Ther"},{"key":"2376_CR98","unstructured":"European Medicines Agency. Annex 1: summary of product characteristics. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160526134685\/anx_134685_en.pdf. Accessed 10 Sept 2025."},{"key":"2376_CR99","unstructured":"Linzess (linaclotide) capsules: US prescribing information. US FDA. 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202811s000lbl.pdf. Accessed 17 Sept 2025."},{"key":"2376_CR100","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40272-021-00444-4","volume":"23","author":"DF Baaleman","year":"2021","unstructured":"Baaleman DF, Gupta S, Benninga MA, Bali N, Vaz KH, Yacob D, et al. The use of linaclotide in children with functional constipation or irritable bowel syndrome: a retrospective chart review. Pediatr Drugs. 2021;23:307\u201314. https:\/\/doi.org\/10.1007\/s40272-021-00444-4.","journal-title":"Pediatr Drugs"},{"issue":"3","key":"2376_CR101","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jpn3.12103","volume":"78","author":"C Di Lorenzo","year":"2024","unstructured":"Di Lorenzo C, Nurko S, Hyams JS, Rodriguez-Araujo G, Shakhnovich V, Saps M, et al. Safety and efficacy of linaclotide in children aged 7\u201317 years with irritable bowel syndrome with constipation. J Pediatr Gastroenterol Nutr. 2024;78(3):539\u201347. https:\/\/doi.org\/10.1002\/jpn3.12103.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"2376_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.295","volume":"5","author":"A Brancale","year":"2017","unstructured":"Brancale A, Shailubhai K, Ferla S, Ricci A, Bassetto M, Jacob GS. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog. Pharmacol Res Perspect. 2017;5(2):e00295. https:\/\/doi.org\/10.1002\/prp2.295.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"2376_CR103","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4292\/wjgpt.v6.i4.213","volume":"6","author":"K Shailubhai","year":"2015","unstructured":"Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, et al. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther. 2015;6(4):213\u201322. https:\/\/doi.org\/10.4292\/wjgpt.v6.i4.213.","journal-title":"World J Gastrointest Pharmacol Ther."},{"issue":"9","key":"2376_CR104","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s10620-013-2684-z","volume":"58","author":"K Shailubhai","year":"2013","unstructured":"Shailubhai K, Comiskey S, Foss JA, Feng R, Barrow L, Comer GM, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580\u20136. https:\/\/doi.org\/10.1007\/s10620-013-2684-z.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"2376_CR105","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1136\/gutjnl-2018-316029","volume":"67","author":"SA Waldman","year":"2018","unstructured":"Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018;67(8):1543\u201352. https:\/\/doi.org\/10.1136\/gutjnl-2018-316029.","journal-title":"Gut"},{"key":"2376_CR106","unstructured":"Trulance (plecanatide) tablets. US prescribing information. US FDA. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208745s001lbl.pdf. Accessed 20 Sept 2025."},{"key":"2376_CR107","unstructured":"Efficacy and safety of plecanatide in children 6 to <18 years of age with irritable bowel syndrome with constipation (IBS-C). 2025. https:\/\/clinicaltrials.gov\/study\/NCT03596905. Accessed 21 Sept 2025."},{"key":"2376_CR108","doi-asserted-by":"publisher","first-page":"G823","DOI":"10.1152\/ajpgi.90447.2008","volume":"296","author":"G Fei","year":"2009","unstructured":"Fei G, Wang YZ, Liu S, Hu HZ, Wang GD, Qu MH, et al. Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol. 2009;296:G823-32. https:\/\/doi.org\/10.1152\/ajpgi.90447.2008.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2376_CR109","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/cia.s2938","volume":"3","author":"BE Lacy","year":"2008","unstructured":"Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3:357\u201364. https:\/\/doi.org\/10.2147\/cia.s2938.","journal-title":"Clin Interv Aging"},{"issue":"5","key":"2376_CR110","doi-asserted-by":"publisher","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","volume":"290","author":"M Camilleri","year":"2006","unstructured":"Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G942-7. https:\/\/doi.org\/10.1152\/ajpgi.00264.2005.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"2376_CR111","doi-asserted-by":"publisher","first-page":"G295","DOI":"10.1152\/ajpgi.90558.2008","volume":"296","author":"S Sweetser","year":"2009","unstructured":"Sweetser S, Busciglio IA, Camilleri M, Bharucha AE, Szarka LA, Papathanasopoulos A, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G295-301. https:\/\/doi.org\/10.1152\/ajpgi.90558.2008.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2376_CR112","unstructured":"Amitiza (lubiprostone) capsules. US prescribing information. US FDA. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021908s010lbl.pdf. Accessed 23 Sept 2025."},{"issue":"3","key":"2376_CR113","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MPG.0000000000000176","volume":"58","author":"P Hyman","year":"2014","unstructured":"Hyman P, Di Lorenzo C, Prestridge L, Youssef NN, Ueno R. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2014;58(3):283\u201391. https:\/\/doi.org\/10.1097\/MPG.0000000000000176.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2376_CR114","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/MPG.0000000000003280","volume":"73","author":"SZ Hussain","year":"2021","unstructured":"Hussain SZ, Labrum B, Mareya S, Stripling S, Clifford R. Safety of lubiprostone in pediatric patients with functional constipation: a nonrandomized, open-label trial. J Pediatr Gastroenterol Nutr. 2021;73(5):572\u20138. https:\/\/doi.org\/10.1097\/MPG.0000000000003280.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2376_CR115","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2021.04.005","volume":"20","author":"MA Benninga","year":"2022","unstructured":"Benninga MA, Hussain SZ, Sood MR, Nurko S, Hyman P, Clifford RA, et al. Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension. Clin Gastroenterol Hepatol. 2022;20(3):602-10.e5. https:\/\/doi.org\/10.1016\/j.cgh.2021.04.005.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"227","key":"2376_CR116","doi-asserted-by":"publisher","first-page":"22736","DOI":"10.1126\/scitranslmed.300779","volume":"6","author":"AG Spencer","year":"2014","unstructured":"Spencer AG, Labonte ED, Rosenbaum DP. Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):22736. https:\/\/doi.org\/10.1126\/scitranslmed.300779.","journal-title":"Sci Transl Med."},{"issue":"5 Suppl.1","key":"2376_CR117","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0016-5085(11)60233-3","volume":"140","author":"H Eutamene","year":"2011","unstructured":"Eutamene H, Charmot, Navre M, Bueno L. Visceral antinociceptive effects of RDX5791, a first-in-class minimally systemic NHE3 inhibitor on stress-induced colorectal hypersensitivity to distension in rats. Gastroenterology. 2011;140(5 Suppl.1):S57\u20138. https:\/\/doi.org\/10.1016\/S0016-5085(11)60233-3.","journal-title":"Gastroenterology"},{"key":"2376_CR118","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.14309\/00000434-201710001-00484","volume":"112","author":"Q Li","year":"2017","unstructured":"Li Q, King A, Liu L, Zhu Y, Caldwell JS, Pasricha PS. Tenapanor reduces IBS pain through inhibition of TRPV1-dependent neuronal hyperexcitability in vivo. Am J Gastroenterol. 2017;112:S255. https:\/\/doi.org\/10.14309\/00000434-201710001-00484.","journal-title":"Am J Gastroenterol"},{"issue":"6 Suppl. 1","key":"2376_CR119","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1016\/S0016-5085(18)31424-0","volume":"154","author":"J Wang","year":"2018","unstructured":"Wang J, Larauche M, Siegel M, King A, Mayer EA, Tillisch K, et al. Tenapanor attenuates increased macromolecule permeability in human colon monolayer cultures induced by inflammatory cytokines and human fecal supernatants. Gastroenterology. 2018;154(6 Suppl. 1):S326. https:\/\/doi.org\/10.1016\/S0016-5085(18)31424-0.","journal-title":"Gastroenterology"},{"key":"2376_CR120","unstructured":"Ibsrela (tenapanor) tablets. US prescribing information. US FDA. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211801s012lbl.pdf. Accessed 25 Sept 2025."},{"key":"2376_CR121","unstructured":"Safety study of tenapanor for the treatment of pediatric patients (6 to less than 18 years old) with IBS-C. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05905926. Accessed 26 Sept 2025."},{"issue":"11","key":"2376_CR122","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/nmo.12896","volume":"28","author":"M Saps","year":"2016","unstructured":"Saps M, Van Tilburg MAL, Lavigne JV, Miranda A, Benninga MA, Taminiau JA, et al. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. Neurogastroenterol Motil. 2016;28(11):1619\u201331. https:\/\/doi.org\/10.1111\/nmo.12896.","journal-title":"Neurogastroenterol Motil"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02376-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:11:54Z","timestamp":1792829514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02376-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":122,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2376"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02376-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.B., M.G.P., A.O.J.O., N.K.V. and M.A.B  have no relevant conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data supporting the findings of this manuscript will be made available by the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.B., guarantor of manuscript; M.G.P., search of literature, first draft of manuscript, and approval of the final version of the paper; A.O.J.O., search of literature, first draft of manuscript, and approval of the final version of the paper; N.K.V., critical revision of the manuscript and approval of the final version of the paper; and M.A.B., critical revision of the manuscript and approval of the final version of the paper.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}